Stay updated on BL-8040/Pembrolizumab Combo in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the BL-8040/Pembrolizumab Combo in Pancreatic Cancer Clinical Trial page.

Latest updates to the BL-8040/Pembrolizumab Combo in Pancreatic Cancer Clinical Trial page
- Check7 days agoChange DetectedAdded Locations entries for Arizona, Louisiana, Massachusetts, Michigan, Missouri, New Jersey, New York, Texas, and Washington, and removed their state-specific location sections; revision updated to v3.3.3.SummaryDifference0.8%

- Check14 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedThe Publications note text was updated to clarify PubMed auto-filling and the revision label changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check43 days agoChange DetectedThe government funding operating-status notice was removed from the page. The removed notice instructed users to check cc.nih.gov and opm.gov for updates.SummaryDifference0.3%

- Check65 days agoChange DetectedNew results data appear on the page, with updated outcome measures and study dates. This expands the core content about the trial's efficacy, safety outcomes, and overall status.SummaryDifference0.3%

- Check86 days agoChange DetectedUpdate includes a prominent operating-status notice and a version upgrade from v3.1.0 to v3.2.0. The core effect is informing users about possible delays and the current open status of the NIH Clinical Center.SummaryDifference2%

- Check93 days agoChange DetectedThe page updates the version from v3.0.2 to v3.1.0, changing the revision identifier. Overall meaning remains the same with an upgraded version tag.SummaryDifference0.1%

Stay in the know with updates to BL-8040/Pembrolizumab Combo in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BL-8040/Pembrolizumab Combo in Pancreatic Cancer Clinical Trial page.